Imipenem in burn patients: Pharmacokinetic profile and PK/PD target attainment

Journal of Antibiotics

Volumn 68, Issue 3, 2015, Pages 143-147

  Gomez, David S ^a   Sanches Giraud, Cristina ^b   Silva, Carlindo V ^a   Oliveira, Amanda M Ribas Rosa ^a   Da Silva, Joao Manoel ^a   Gemperli, Rolf ^a   Santos, Silvia R C J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IMIPENEM; ANTIINFECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BURN; BURN PATIENT; CHEMICAL INJURY; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; ELECTRIC INJURY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PARAMETERS; PHARMACODYNAMICS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROBABILITY OF TARGET ATTAINMENT; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; SKIN SURFACE; STATISTICAL ANALYSIS; THERMAL INJURY; TOTAL BURN SURFACE AREA; ULTRAFILTRATION; VOLUME OF DISTRIBUTION; ADOLESCENT; BURNS; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; PROBABILITY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BURNS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES;

EID: 84925709745     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.121     Document Type: Article

References (13)

1. Fry, D. E. The importance of antibiotic pharmacokinetics in critical illness. Am. J. Surg. 172, 20S-25S (1996).
2. Weinbren, M. J. Pharmacokinetics of antibiotics in burn patients. J. Antimicrob. Chemother. 44, 319-327 (1999).
3. Blanchet, B., Jullien, V., Vinsonneau, C., Tod, M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin. Pharmacokinet. 47, 635-654 (2008).
4. Scaglione, F. Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteremia. Int. J. Antimicrob. Agents 36S, S33-S39 (2010).
5. Varghese, J. M., Roberts, J. A., Lipman, J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit. Care Clin. 27, 19-34 (2011).
6. Boucher, B. A., Hickerson, W. L., Kuhl, D. A., Bombassaro, A. M., Jaresko, G. S. Imipenem pharmacokinetics in patients with burns. Clin. Pharmacol. Ther. 48, 130-137 (1990).
7. Dailly, E., Kergueris, M. F., Pannier, M., Jolliet, P., Bourin, M. Population pharmacokinetics of imipenem in burn patients. Fundam. Clin. Pharmacol. 17, 645-650 (2003).
8. Cockcroft, D. W., Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
9. European Committee of Antimicrobial Susceptibility Testing. MIC distribution, available on www.eucast.org/mic-distributions/ accessed 2013-2014.
10. Ikawa, K., Morikawa, N., Ohge, K. I. H., Sueda, T. Development of breakpoints of carbapenems for intra-abdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid. J. Infect. Chemother. 14, 330-332 (2008).
11. Drusano, G. L. et al. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob. Agents Chemother. 26, 715-721 (1984).
12. Belzberg, H. et al. Imipenem levels are not predictable in the critically ill patient. J. Trauma 56, 111-117 (2004).
13. Schmidt, S., Barbour, A., Sahre, M., Rand, K. H., Derendorf, H. PK/PD: new insights for antibacterial and antiviral applications. Curr. Opin. Pharmacol. 8, 549-556 (2008).